Affordable Access

deepdyve-link
Publisher Website

Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point.

Authors
  • Bartus, Raymond T
  • Herzog, Christopher D
  • Bishop, Kathie
  • Ostrove, Jeffrey M
  • Tuszynski, Mark
  • Kordower, Jeffrey H
  • Gasmi, Mehdi
Type
Published Article
Journal
Parkinsonism & Related Disorders
Publisher
Elsevier
Publication Date
Jan 01, 2007
Volume
13 Suppl 3
Identifiers
DOI: 10.1016/S1353-8020(08)70052-X
PMID: 18267286
Source
Medline
License
Unknown

Abstract

CERE-120 may represent an important, novel therapy for PD, though the clinical data require confirmation with additional clinical tests, including an ongoing multi-center, double-blinded controlled trial.

Report this publication

Statistics

Seen <100 times